Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 4;8(6):706–717. doi: 10.1093/nop/npab054

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Variations in aspects of clinical management of diffuse low-grade glioma across the 11 included centers (A–K), ranked from lowest to highest percentage. The dotted line marks the mean percentage. CHT: chemotherapy; PCV: procarbazine, lomustine, vincristine; RT: radiotherapy; TMZ: temozolomide. ^aTime from radiological diagnosis to surgical resection. ^bInitiation of radiotherapy within 6 months postoperatively. ^cMutational status of IDH and 1p/19q assessed. ^dUse of intraoperative brain mapping during tumor resections in presumed eloquent brain regions. ^eDiffusion tensor imaging (DTI), functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET).

Figure 1. — Variations in aspects of clinical management of diffuse low-grade glioma across the 11 included centers (A–K), ranked from lowest to highest percentage. The dotted line marks the mean percentage. CHT: chemotherapy; PCV: procarbazine, lomustine, vincristine; RT: radiotherapy; TMZ: temozolomide. ^aTime from radiological diagnosis to surgical resection. ^bInitiation of radiotherapy within 6 months postoperatively. ^cMutational status of IDH and 1p/19q assessed. ^dUse of intraoperative brain mapping during tumor resections in presumed eloquent brain regions. ^eDiffusion tensor imaging (DTI), functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET).